GLP-2 Peptide 60 MG

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist.
It is studied for its effects on weight loss, glucose control, and cardiometabolic outcomes, and represents a new generation of incretin-based therapies.

BENEFITS

• Weight loss — studied for significant body weight reductions in clinical trials.
• Glucose control — linked to improved HbA1c and insulin sensitivity in type 2 diabetes.
• Cardiometabolic health — explored for lipid balance and reduced cardiovascular risk markers.
• Energy balance — dual GIP/GLP-1 action offers metabolic synergy.
• Next-gen incretin therapy — combines multiple pathways for broader efficacy.

WHAT RESEARCHERS LOOK AT

• Dual incretin agonism: GIP + GLP-1 receptor activation.
• SURPASS clinical trial program results in type 2 diabetes and obesity.
• Comparisons to GLP-1 agonists (e.g., semaglutide) for weight and glycemic control.
• Exploration of long-term cardiovascular outcomes and liver health.

QUICK SPECS

• Form: Lyophilized peptide
• Net per vial: 60 mg
• Purity: ≥99% (HPLC)
• Identity: MS-verified (per COA)
• Storage: 2–8 °C, protect from light

IDENTITY BASICS

• Type: Dual GIP/GLP-1 receptor agonist
• Formula / M.W.: Peptide analog (varies by formulation)

SELECTED RESEARCH

• PubChem entry — chemical identity:
  
  https://pubchem.ncbi.nlm.nih.gov/compound/137329144
  
• SURPASS trials overview (2021):
  
  https://pubmed.ncbi.nlm.nih.gov/34170647/
  
• Weight loss and glycemic outcomes (NEJM, 2021):
  
  https://pubmed.ncbi.nlm.nih.gov/34170646/
  
• Cardiometabolic and lipid effects:
  
  https://pubmed.ncbi.nlm.nih.gov/36718633/
  

DISCLAIMER

• This product is intended for laboratory research use only.

• Not for human or veterinary use.

• Not approved for diagnostic, therapeutic, or medical applications.

• Handle using appropriate laboratory safety procedures and personal protective equipment.